09:42     GOLDIGIT ATOM<02362>-Announcement & Resumption of Trading-5         

    scope of the Group's business into biotech and                            
    pharmaceutical sector and presents a good opportunity                     
    for the Company to tap into the lucrative                                 
    pharmaceutical business in China. Although there are                      
    risks involved in venturing into the pharmaceutical                       
    business in the PRC, the Directors consider that                          
    Beijing Aleznova is a fast-growing company with                           
    competent and experienced management. Also, the                           
    Directors consider that the proportionate market                          
    value of the licenses of the Cat I Drugs alone shall                      
    substantially exceed the investment cost of the                           
    Company.                                                                  
                                                                              
    In view of the above, the Directors (including                            
    Independent Non-Executive Directors) consider the                         
    terms and conditions of the Acquisition are fair and                      
    reasonable and in the interests of the Company and                        
    the shareholders as a whole.                                              
                                                                              
    GENERAL                                                                   
    The principal activity of the Company is investment                       
    holding. The Group is principally engaged in                              
    pesticides distribution and development. The                              
    Acquisition constitutes a discloseable transaction                        
    under Chapter 14 of the Listing Rules. A circular                         
    containing details of the Acquisition will be                             
    despatched to the Shareholders as soon as                                 
    practicable.                                                              
                                                                              
    The information relating to the Acquisition may be                        
    of price sensitive nature pursuant to Rule 13.09 of                       
    the Listing Rules. Shareholders and potential                             
    investors should exercise caution when dealing in the                     
    shares of the Company.                                                    
                                                                              
    At the request of the Company, trading in the Shares                      
    was suspended with effect from 9:30 a.m. on 11 March                      
    2005, pending release of this announcement.                               
    Application has been made by the Company for the                          
    resumption of trading in the Shares with effect from                      
    9:30 a.m. on 17 March 2005.                                               
                                                                              
    The announcement appears for information purposes                         
    only and does not constitute an invitation or offer                       
    to acquire, purchase or subscribe for the securities.                     
                                                                              
    DEFINITIONS                                                               
    "Acquisition"   the acquisition of 20% of the issued                      
    shares capital by the Purchaser from the Vendor                           
    pursuant to the Agreement                                                 
                                                                              
    "Agreement"     the agreement dated 10 March 2005 entered                 
    into between the Vendor and the Purchaser in relation                     
    to the Acquisition                                                        
                                                                              
    Beijing Aleznova        *                                                 
    (Beijing Aleznova Pharmaceutical Research Institute                       
    Company Limited), a company incorporated in the PRC                       
    with limited liability. Golden Crown is the sole                          
    shareholder of Beijing Aleznova                                           
                                                                              
    "Board" the board of Directors of the Company                             
                                                                              
    "Company"       Goldigit Atom-tech Holdings Limited, a                    
    company incorporated in the Cayman Islands with                           
    limited liability, whose shares are listed on the                         
    Stock Exchange                                                            
                                                                              
    "Completion"    completion of the Acquisition                             
                                                                              
    "Completion Date"       10 April 2005 or other date as                    
    agreed by the Purchaser and the Vendor